CHAIRMAN'S LETTER
I am pleased to present Immutep’s Annual Report for the 2018 financial year. This is my first Annual Report as your Chairman and our first Annual Report as Immutep Limited, after changing the Company’s name from Prima BioMed Ltd to Immutep Limited at our Annual General Meeting in November 2017.
It has been an exceptionally busy and successful year for Immutep, particularly in terms of clinical development achievements that place us in a leadership position in the LAG-3 immunotherapy field, as well as with corporate achievements that have solidified the Company’s strategy.
To view Report please download PDF attached:
Download this document
